Global Hormone Refractory Prostate Cancer Market Expansion at 10.1% CAGR, Valued at $11.91 Billion by 2029

Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.

What Are the Hormone Refractory Prostate Cancer Market Size Forecast for 2025?
The market size for hormone-refractory prostate cancer has seen a swift expansion in the past few years. Projections indicate an escalation from $7.35 billion in 2024 to $8.12 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.4%. The historic growth can be credited to factors such as the rising occurrence of prostate cancer, an upsurge in PSA (prostate-specific antigen) screenings, enhanced physician awareness and specialization, a growth in the use of palliative care, and an increased count of clinical trials.

What Is the Market Size Outlook for Hormone Refractory Prostate Cancer Until 2029?
The market size of hormone-refractory prostate cancer is expected to undergo considerable expansion in the coming years, rising to $11.91 billion by 2029 with a compound annual growth rate (CAGR) of 10.1%. This projected growth can be attributed to various factors, such as the escalating use of genetic biomarkers, increased utilization of precision medicine, expansion of PARP inhibitors, growing global accessibility to HRPC treatments, and increased clinical employment of combination regimens. Other notable trends anticipated during this forecast period include combination therapies adoption, advancements in radiopharmaceuticals, deployment of next-generation sequencing (NGS), incorporation of digital tools and remote monitoring, and the development of next-generation androgen receptor inhibitors and PARP inhibitors for HRPC.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/hormone-refractory-prostate-cancer-global-market-report

What Are the Major Factors Driving Demand in the Hormone Refractory Prostate Cancer Market?
The hormone-refractory prostate cancer market is predicted to expand due to the increasing investment in cancer research. The capital and resources dedicated to cancer research are essential for the development of innovative methods for cancer detection, prevention, and treatment. The escalating worldwide cancer burden necessitates greater investment in cancer research, which in turn leads to more advanced and targeted treatments. Through such investments, innovative treatments for hormone-refractory prostate cancer, like radioligand treatments and hormone inhibitors, have been made possible. Additionally, these research funds also support clinical trials and biomarker research, thereby maximising treatment accuracy and improving outcomes. For example, the Cancer Research Institute (CRI), a nonprofit organisation based in the US that is committed to promoting immunotherapy research, invested approximately $22.8 million in the 2023-2024 fiscal years, providing funding for 64 new grants to researchers at 42 institutions across seven countries. Consequently, the rising funding for cancer research fuels the expansion of the hormone-refractory prostate cancer market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25786&type=smp

How Are End-Use Segments Shaping the Hormone Refractory Prostate Cancer Market Outlook?
The hormone refractory prostate cancer market covered in this report is segmented -

1) By Treatment Type: Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

Subsegments:
1) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Estramustin
2) By Hormonal Therapy: Anti-Androgens, CYP17 Inhibitors, LHRH Agonists, LHRH Antagonists
3) By Immunotherapy: Cancer Vaccines, Immune Checkpoint Inhibitors, Adoptive Cell Therapy
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy, Radionuclide Therapy
5) By Surgery: Radical Prostatectomy, Orchiectomy, Transurethral Resection Of The Prostate (TURP)

What Are the Strategic Trends Transforming the Hormone Refractory Prostate Cancer Market Landscape?
Significant players in the hormone-refractory prostate cancer market are concentrating on the development of advanced treatment options like intravenous radioligand therapy in order to enhance survival rates for those suffering from resistant variants of the condition. By attaching radioactive molecules to ligands, intravenous radioligand therapy specifically targets and eradicates cancer cells, leaving surrounding healthy tissue unaffected. For example, in March 2025, the Switzerland-based pharmaceutical company Novartis AG introduced Pluvicto (lutetium Lu 177 vipivotide tetraxetan), cleared by the Food and Drug Administration (FDA), for early-stage use in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) patients who have already undergone an androgen receptor pathway inhibitor (ARPI) treatment and are suitable for a deferred chemotherapy. The widened use of Pluvicto, backed by the Phase III PSMAfore study, has tripled the number of potential beneficiaries and revealed a promising reduction of 59% in the risk of radiographic progression or death, while also increasing the median radiographic progression-free survival in comparison to an ARPI shift. Pluvicto stands as the first approved radioligand therapy for pre-chemotherapy application in this context, constituting a promising new therapeutic alternative capable of delaying disease progression while ensuring an acceptable safety profile.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25786&type=smp

Who Are the Prominent Companies in the Hormone Refractory Prostate Cancer Market by ?
Major companies operating in the hormone refractory prostate cancer market are Pfizer Inc., Johnson And Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Ipsen Pharma, Exelixis Inc., Orion Corporation, Lantheus Holdings Inc., Clovis Oncology Inc., Telix Pharmaceuticals, Dendreon Pharmaceuticals LLC

Which Region Is Expected to See the Highest CAGR in the Hormone Refractory Prostate Cancer Market?
North America was the largest region in the hormone-refractory prostate cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hormone refractory prostate cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.